Business
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
NXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious co
About this update from Nuvectis Pharma, Inc.
[{"type":"image","alt":"Nuvectis Pharma, Inc.","displaySize":"","headline":null,"caption":"Nuvectis Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nRG6U8qyRov.rdo5jgBvoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMw--/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d","width":300,"height":152}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":247,"olType":false},{"type":"text","content":"FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.","length":434,"tagName":"p"},{"type":"text","content":"Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2026 is off to a good start for Nuvectis as we advance the NXP900 Phase 1b clinical program which continues to enroll patients at top sites in the US in both the monotherapy and combination arms of the program." Mr. Bentsur added, "At this year’s AACR conference held last month, we provided preclinical data supporting the use of NXP900 in combination with sotorasib, a RAS inhibitor, in non-small cell lung cancer (NSCLC). The combination demonstrated clear synergy both in sotorasib-sensitive and sotorasib-resistant NSCLC models."","length":629,"tagName":"p"},{"type":"text","content":"Mr. Bentsur concluded, "We are excited for what’s ahead in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer. We continue to operate with financial discipline ...